Evidence map›Paper›PMID 35127770›Full record

ArticleFrontiers in medicine2021

Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021.

Francesca Colavita, Silvia Meschi, Cesare Ernesto Maria Gruber, Martina Rueca, Francesco Vairo, Giulia Matusali, Daniele Lapa, Emanuela Giombini, Gabriella De Carli, Martina Spaziante and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Francesca ColavitaNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Silvia MeschiNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Cesare Ernesto Maria GruberNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Martina RuecaNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Francesco VairoNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Giulia MatusaliNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Daniele LapaNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Emanuela GiombiniNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Gabriella De CarliNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Martina SpazianteNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Francesco MessinaNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Giulia BonfiglioNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Fabrizio CarlettiNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Eleonora LalleNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Lavinia FabeniNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Giulia BernoNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Vincenzo PuroNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Barbara BartoliniNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Antonino Di CaroNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Giuseppe IppolitoNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Maria Rosaria CapobianchiNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Concetta CastillettiNational Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Roma, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Nazionale per le Malattie Infettive Lazzaro Spallanzani · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccines for coronavirus disease 2019 (COVID-19) are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study focuses on virological and serological features of 94 infections that occurred in Lazio Region (Central Italy) between 27 December 2020, and 30 March 2021, after one or two doses of mRNA BNT162b2 vaccine.

methodsWe evaluated clinical features, virological (viral load; viral infectiousness; genomic characterisation), and serological (anti-nucleoprotein Ig; anti-Spike RBD IgG; neutralising antibodies, nAb) characteristics of 94 post-vaccine infections at the time of diagnosis. Nasopharyngeal swabs (NPSs) and serum samples were collected in the framework of the surveillance activities on SARS-CoV-2 variants established in Lazio Region (Central Italy) and analysed at the National Institute for Infectious Diseases "L. Spallanzani" in Rome.

resultsThe majority (92.6%) of the post-vaccine infections showed pauci/asymptomatic or mild clinical course, with symptoms and hospitalisation rate significantly less frequent in patients infected after full vaccination course as compared to patients who received a single dose vaccine. Although differences were not statistically significant, viral loads and isolation rates were lower in NPSs from patients infected after receiving two vaccine doses as compared to patients with one dose. Most cases (84%) had nAb in serum at the time of infection diagnosis, which is a sub-group of vaccinees, were found similarly able to neutralise Alpha and Gamma variants. Asymptomatic individuals showed higher nAb titres as compared to symptomatic cases (median titre: 1:120 vs. 1:40, respectively). Finally, the proportion of post-vaccine infections attributed either to Alpha and Gamma variants was similar to the proportion observed in the contemporary unvaccinated population in the Lazio region, and mutational analysis did not reveal enrichment of a defined set of Spike protein substitutions depending on the vaccination status.

conclusionOur study conducted using real-life data, emphasised the importance of monitoring vaccine breakthrough infections, through the characterisation of virological, immunological, and clinical features associated with these events, in order to tune prevention measures in the next phase of the COVID-19 pandemic.

Indexed as

breakthrough infectionCOVID-19Italyneutralising antibodiesSARS-CoV-2vaccineviral variants

Identifiers

PMID35127770
PMCPMC8810639
OpenAlexW4205867961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.